Alexandra J. Sinclair

Birmingham, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 143 publications

Cerebrospinal fluid shunting or dural venous sinus stenting to preserve vision in idiopathic intracranial hypertension (IIH Intervention): protocol for an open-label, multicentre, randomised controlled phase IIb trial.

Cerebrospinal fluid shunting or dural venous sinus stenting to preserve vision in idiopathic intracranial hypertension (IIH Intervention): protocol for an open-label, multicentre, randomised controlled phase IIb trial.

Journal: BMJ open
Published: August 03, 2026

Letter to the Editor. Enhancing comparability in idiopathic intracranial hypertension research through standardized outcome measures.

Letter to the Editor. Enhancing comparability in idiopathic intracranial hypertension research through standardized outcome measures.

Journal: Neurosurgical focus
Published: July 01, 2026

Identifying MicroRNA Biomarkers in Idiopathic Intracranial Hypertension: A Pilot Study.

Identifying MicroRNA Biomarkers in Idiopathic Intracranial Hypertension: A Pilot Study.

Journal: Neurology
Published: June 17, 2026

Migraine-advanced preventative treatments: the British Association for the Study of Headache Clinical Practice Recommendations and Consensus Guidance.

Migraine-advanced preventative treatments: the British Association for the Study of Headache Clinical Practice Recommendations and Consensus Guidance.

Journal: Journal of neurology, neurosurgery, and psychiatry
Published: April 13, 2026

CGRP-provoked headache is associated with a neuroimmune signature in idiopathic intracranial hypertension.

CGRP-provoked headache is associated with a neuroimmune signature in idiopathic intracranial hypertension.

Journal: The journal of headache and pain
Published: March 18, 2026

Pro-Con: Antiobesity Drugs Such as Glucagon-Like Peptide-1 Receptor Agonists Should Be a First-Line Treatment in Idiopathic Intracranial Hypertension.

Pro-Con: Antiobesity Drugs Such as Glucagon-Like Peptide-1 Receptor Agonists Should Be a First-Line Treatment in Idiopathic Intracranial Hypertension.

Journal: Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
Published: February 17, 2026

Reconceptualizing intracranial pressure: the role of amplitude in comprehensive reporting.

Reconceptualizing intracranial pressure: the role of amplitude in comprehensive reporting.

Journal: Journal of neurosurgery
Published: January 22, 2026

Spaceflight-associated neuro-ocular syndrome (SANS): expert consensus on diagnosis and management.

Spaceflight-associated neuro-ocular syndrome (SANS): expert consensus on diagnosis and management.

Journal: Eye (London, England)
Published: December 30, 2025

Comment on "Surgical versus endovascular treatment for idiopathic intracranial hypertension".

Comment on "Surgical versus endovascular treatment for idiopathic intracranial hypertension".

Journal: Neuro-Chirurgie
Published: November 06, 2025

Stenting versus shunting in sight-threatening idiopathic intracranial hypertension: genuine equipoise.

Stenting versus shunting in sight-threatening idiopathic intracranial hypertension: genuine equipoise.

Journal: Practical neurology
Published: November 05, 2025

Moderate to Severe Acute Migraine Attacks: An Opinion Paper on the Use of Triptans and Triptan-NSAIDs Combinations in Individualized Treatment Plans.

Moderate to Severe Acute Migraine Attacks: An Opinion Paper on the Use of Triptans and Triptan-NSAIDs Combinations in Individualized Treatment Plans.

Journal: Neurology and therapy
Published: November 03, 2025

Calcitonin gene-related peptide induces headache attacks in people with idiopathic intracranial hypertension.

Calcitonin gene-related peptide induces headache attacks in people with idiopathic intracranial hypertension.

Journal: Brain : a journal of neurology
Published: October 25, 2025
Showing 1-12 of 143

Last Updated: 09/26/2026